Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Atea Pharmaceuticals (AVIR) Net Income towards Common Stockholders (2019 - 2026)

Atea Pharmaceuticals' Net Income towards Common Stockholders history spans 8 years, with the latest figure at -$45.4 million for Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 32.59% to -$45.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$169.5 million through Mar 2026, down 21.53% year-over-year, with the annual reading at -$158.3 million for FY2025, 5.96% up from the prior year.
  • Net Income towards Common Stockholders came in at -$45.4 million for Q1 2026, down from -$44.9 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$8.1 million in Q3 2022 to a low of -$63.2 million in Q1 2024.
  • The 5-year median for Net Income towards Common Stockholders is -$35.5 million (2023), against an average of -$36.7 million.
  • The largest YoY upside for Net Income towards Common Stockholders was 71.39% in 2022 against a maximum downside of 2136.06% in 2022.
  • Atea Pharmaceuticals' Net Income towards Common Stockholders stood at -$34.4 million in 2022, then fell by 13.75% to -$39.2 million in 2023, then grew by 14.35% to -$33.5 million in 2024, then plummeted by 33.76% to -$44.9 million in 2025, then dropped by 1.28% to -$45.4 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Net Income towards Common Stockholders are -$45.4 million (Q1 2026), -$44.9 million (Q4 2025), and -$42.0 million (Q3 2025).